Skip to content
Screener

DBV Technologies DBVT Financing Cash Flow

Financing Cash Flow at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$410.21M+87,565%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$1.1M+195%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$4.42M-78.6%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$324.66M+515,229%
Alumis Inc. logo
Alumis Inc.ALMS
$346.99M
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$529.55M+7,564,886%

Other financials

Income statement

See full
Revenue$700.0K-53.3%
Operating income-$50.6M-23.1%
Net income-$50.4M-20.3%
EPS (diluted)-$0.12+61.3%

Balance sheet

See full
Cash & equivalents$174.9M+69.5%
Total debt$7.7M+0.1%
Total equity$160.4M+86.1%
Total assets$223.2M+55.6%

Cash flow

See full
Operating cash flow-$52.6M-55.2%
CapEx$400.0K
Free cash flow-$53.0M-56.3%

Valuation

See full
Market cap$847.16M+218%
Enterprise value$679.96M+297%
P/S168.8×+100×

Profitability

See full
Operating margin-3,543.1%+523pp
Net margin-3,506.5%+442pp
FCF margin-3,399.3%+3,268pp

Returns & leverage

See full
Return on equity-142.7%-5.0pp
Debt / equity0.0×
Current ratio3.7×+1.3×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: DBV Technologies’s 10-Q, filed July 16, 2026.

Filed
Jul 16, 2026, 4:08 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-048453
Line itemNotesSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Cash flows provided by financing activities :
Treasury shares0.1
Issuance from Net Capital increase and Share warrants889.0116.9
Net cash flows provided by financing activities89.0117.0
Effect of exchange rate changes on cash and cash equivalents(5.6)7.7
Net (decrease) / increase in cash and cash equivalents(19.2)70.8
Net Cash and cash equivalents at the beginning of the period3194.232.5
Net cash and cash equivalents at the end of the period3$174.9103.2

Item 1C. Condensed Consolidated Statements of Financial Position (Unaudited) as of

FAQ

What is DBV Technologies's financing cash flow?
DBV Technologies (DBVT) reported financing cash flow of $100K in Q2 2026.
How has DBV Technologies's financing cash flow changed year-over-year?
DBV Technologies's financing cash flow decreased by 99.9% year-over-year, from $117M to $100K.
What is the long-term trend for DBV Technologies's financing cash flow?
Over 2 years (2021 to 2025), DBV Technologies's financing cash flow has grown at a 3074.8% compound annual growth rate (CAGR), from $274K to $276.18M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about DBV Technologies's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude